Market Access Today’s Post

Vaccines are one of the most critical tools in protection against infectious diseases, and continuous innovation and collaboration are essential to address the evolving prevention challenges we face. I was pleased to recently author an article for European Pharmaceutical Review 'Pharma Horizons: Biologics report' (page 5), where I explore the evolving vaccine landscape, how we can overcome key challenges to develop vaccines faster and more efficiently, and my outlook for the future of vaccine development. At Valneva, we are committed to advancing vaccines to improve lives, particularly for diseases with significant unmet medical need. With pressing global health challenges, including the rise of mosquito-borne diseases due to climate change, it’s important to focus on innovative solutions. By leveraging science and creative solutions, we can collectively help protect global health. To discover more, download the report below: https://lnkd.in/eAfkBRnU   #AdvancingVaccinesForBetterLives #vaccine #mosquitobornedisease #science #globalhealth #publichealth

Valneva and Pfizer Present Results from the P-II (VLA15-221) Study of VLA15 Vaccine for Lyme Disease #valneva #pfizer #vla15 #lymedisease #clinicaltrial #phase2 #vaccine #immunogenicity #phase3

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

As viral disease pandemics pose an increasing risk to human health, the need for improved #influenza surveillance and faster, safer vaccine development is more critical than ever. The Fluhema Hemagglutination Analyzer by SciRobotics empowers surveillance laboratories, such as those at the WHO and the CDC, as well as leading vaccine developers like Moderna and other major pharmaceutical companies, to enhance their clinical trials and streamline the development process. #vaccine #influenza #labautomation #hemagglutination

In May, the online discussions among healthcare professionals (HCPs) regarding pharmaceutical companies primarily revolved around three key topics: 1. An app created by Abbott to assess the risk of death or hospitalisation in patients with heart failure. 2. AstraZeneca's decision to withdraw its COVID-19 vaccine. 3. A second fire occurring at the Novo Nordisk headquarters in Denmark. For detailed insights into the sentiments expressed concerning these events, please refer to the full tracker. https://lnkd.in/emHBAFjs #pharma #healthcare #COVID19

Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize COVID-19 Vaccine and Develop Novel Flu-COVID-19 Combination Vaccines - Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards - Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enhanced convenience and protection Read the Sanofi Press Release: https://lnkd.in/ebJxEZtW Read the Novavax Press Release: https://lnkd.in/dTW5zzas

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #biotech #pharma

Continuous improvement of FEV1 in severe eosinophilic asthmatics on anti-interleukin-5 therapy. First author:Alain Michils; corresponding author: Alain Van Muylem Read the article here: doi.org/10.1111/all.16139 In a retrospective study, Michils et al. evaluate the FEV1 trajectory in severe eosinophilic asthmatics receiving treatment with IL-5-targeting biologics. #Allergy_journal Read more articles published in #Allergy on #biologics here: https://lnkd.in/dVsjXuR8

Prima RNApols™ are compatible with any DNA template sequence and length, facilitating the manufacturability of long mRNAs (>10 kb) for self-amplifying mRNA-based drugs, and achieving higher yields per DNA template unit. Work with us: https://bit.ly/3XTud85 #PrimroseBio #PrimaRNApols #mRNA #vaccines #therapeutics

KCAS Bio - Lyon is excited to participate in the 15th Open Scientific EIP Symposium on the Immunogenicity of Biopharmaceuticals. Christine BAIN and Alain POYAU will be delighted to engage in discussions regarding immnogenicity assays and their clinical implications. Additionally, our team will showcase a scientific poster titled "Monitoring immunogenicity of your candidate vaccine by ELISpot: How to reduce assay variability?" https://lnkd.in/gWQdzBjR #EIP #Immunogenicity #Vaccines #ELISpot